Delivered December 16, 2019. Contributor: Teresa W.
To gain a better understanding of the oncology market including the major players, market size and projected growth.
The market size of the oncology drug market in 2018 was $77.3 billion.
The estimated CAGR through 2026 is estimated at 12.3%.
Major drivers of growth include increasing levels of drug approval, emergence of biosimilar drugs, and increasing healthcare costs fueling the need for research and development into new drug alternatives.
There have been over 400 mergers and acquisitions between companies "in the gene therapy, immuno-oncology, microbiome and orphan drugs therapeutic space" in North American since 2014.
Globally since 2014, there have been 2,882 deals in this space.
Top 10 Oncology Companies
The top 10 oncology drug companies based off of oncology department revenue are:
Roche Holding AG: $25.659 billion.
Celgene Corporation : $13.657 billion
Novartis AG : $11.811 billion
Bristol-Myers Squibb Company : $10.312 billion
Johnson & Johnson : $9.844 billion
Merck & Co., Inc. : $8.243 billion
Pfizer Inc. : $7.202 billion
AstraZeneca PLC : $6.028 billion
Eli Lilly : $4.260 billion
AbbVie Inc. : $3.934 billion
Roche is one of the largest biopharmaceutical companies in the world with drug developement in oncology, nueroscience, infectious disease, immunology, cardiovascular, ophthalmology, haemophilia, and respiratory.
In terms of oncology, Roche's focus is on breast cancer, bladder cancer, cervical cancer, colorectal cancer, lung cancer, haematology, liver cancer, skin cancer, ovarian cancer, and renal cell carcinoma.
In August 2019, the FDA approved Roche's Rozlytrek for use in patients with "ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours."